Loading clinical trials...
Loading clinical trials...
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone
Conditions
Interventions
Tomivosertib (eFT-508)
Locations
19
United States
University of Arizona - Cancer Center
Tucson, Arizona, United States
Pacific Shores Medical Group
Long Beach, California, United States
Hoag Memorial Hospital Presbyterian
Los Angeles, California, United States
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States
St. Mary's Medical Center
San Francisco, California, United States
St. Joseph Heritage Healthcare
Santa Rosa, California, United States
Start Date
July 25, 2018
Primary Completion Date
January 31, 2021
Completion Date
June 30, 2021
Last Updated
March 22, 2023
NCT06898450
NCT06658951
NCT05719558
NCT05101070
NCT06307795
NCT06716138
Lead Sponsor
Effector Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions